Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04593823 · ClinicalTrials.gov registry record · Phase 2
Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study
A Phase 2 study, sponsored by scPharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT04593823: Completed Phase 2 study, sponsored by scPharmaceuticals.
NCT04593823 is a Phase 2 study that has completed, run by scPharmaceuticals. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04593823, a Phase 2 study, has completed, sponsored by scPharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, open label, controlled study evaluating the effectiveness, and safety of the Furoscix Infusor vs continued medical therapy in patients with chronic heart failure and fluid overload requiring augmentation in diuretic therapy outside of acute care setting. The study drug, Furoscix (furosemide injection 8 mg/ml), is a furosemide solution buffered to a neutral pH containing 80 mg/10 mL for subcutaneous administration over 5 hours via the Furoscix Infusor. The study objectives are: 1. To provide pilot data on the effectiveness and safety to inform a pivotal trial. 2. To inform population enrichment strategies 3. To refine pivotal trial endpoints and analytical methods 4. To identify operational challenges of study design 5. To assess patient adherence, competence, and experience 6. To familiarize staff and patients with device application and use
Interventions
- COMBINATION_PRODUCT Furoscix Infusor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2022-04-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04593823
The ClinicalTrials.gov registry entry for NCT04593823 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is scPharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Furoscix Infusor is the first listed.
NCT04593823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04593823 about?
NCT04593823 is a clinical study titled "Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study". This is a multicenter, randomized, open label, controlled study evaluating the effectiveness, and safety of the Furoscix Infusor vs continued medical therapy in patients with chronic heart failure and fluid overload requiring augmentation in diuretic therapy outside of acute care setting. The study...
What is the current status of trial NCT04593823?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2021-05-03. Estimated completion is 2022-04-18.
What interventions are being tested in trial NCT04593823?
The interventions under investigation include: Furoscix Infusor (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04593823?
This trial is sponsored by scPharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.